Cargando…

Is vaccine hesitancy justified? Benchmarking post-market vaccine risks with five commonly used medicinal products in Canada

OBJECTIVE: Although vaccines are one of the most cost-effective, low-risk healthcare approaches that save thousands of lives every year, paradoxical fear about vaccine safety is a major roadblock for achieving widespread vaccination coverage. The objective of this study is to change public perceptio...

Descripción completa

Detalles Bibliográficos
Autores principales: Maity, Tuhin, von Schlegell, Ahmad, Longo, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853333/
https://www.ncbi.nlm.nih.gov/pubmed/35149970
http://dx.doi.org/10.17269/s41997-022-00609-9
_version_ 1784653210308313088
author Maity, Tuhin
von Schlegell, Ahmad
Longo, Christopher
author_facet Maity, Tuhin
von Schlegell, Ahmad
Longo, Christopher
author_sort Maity, Tuhin
collection PubMed
description OBJECTIVE: Although vaccines are one of the most cost-effective, low-risk healthcare approaches that save thousands of lives every year, paradoxical fear about vaccine safety is a major roadblock for achieving widespread vaccination coverage. The objective of this study is to change public perception of vaccine safety by presenting real-world incidence of adverse events following immunization (AEFIs). METHODS: In this study, we used Canadian post-market adverse events data to estimate the real-world risk of AEFI and benchmarked them against five commonly used drug types—ACE inhibitors, beta2 adrenergic receptors, penicillins, proton pump inhibitors, and HMG-CoA reductase inhibitors. RESULTS: Our analysis shows that post-market AEFIs are rare, and vaccination generally carries a significantly lower risk compared to some commonly used medicinal product types. CONCLUSION: Despite some limitations with using post-trial adverse events data, we believe that the evidence presented in this study, especially the comparative risk analysis between vaccines and medicinal products, when communicated through proper channels, can help vaccine-hesitant individuals overcome their perceived safety concerns with regard to vaccines.
format Online
Article
Text
id pubmed-8853333
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-88533332022-02-18 Is vaccine hesitancy justified? Benchmarking post-market vaccine risks with five commonly used medicinal products in Canada Maity, Tuhin von Schlegell, Ahmad Longo, Christopher Can J Public Health Special Section on COVID-19: Quantitative Research OBJECTIVE: Although vaccines are one of the most cost-effective, low-risk healthcare approaches that save thousands of lives every year, paradoxical fear about vaccine safety is a major roadblock for achieving widespread vaccination coverage. The objective of this study is to change public perception of vaccine safety by presenting real-world incidence of adverse events following immunization (AEFIs). METHODS: In this study, we used Canadian post-market adverse events data to estimate the real-world risk of AEFI and benchmarked them against five commonly used drug types—ACE inhibitors, beta2 adrenergic receptors, penicillins, proton pump inhibitors, and HMG-CoA reductase inhibitors. RESULTS: Our analysis shows that post-market AEFIs are rare, and vaccination generally carries a significantly lower risk compared to some commonly used medicinal product types. CONCLUSION: Despite some limitations with using post-trial adverse events data, we believe that the evidence presented in this study, especially the comparative risk analysis between vaccines and medicinal products, when communicated through proper channels, can help vaccine-hesitant individuals overcome their perceived safety concerns with regard to vaccines. Springer International Publishing 2022-02-11 /pmc/articles/PMC8853333/ /pubmed/35149970 http://dx.doi.org/10.17269/s41997-022-00609-9 Text en © The Author(s) under exclusive license to The Canadian Public Health Association 2022
spellingShingle Special Section on COVID-19: Quantitative Research
Maity, Tuhin
von Schlegell, Ahmad
Longo, Christopher
Is vaccine hesitancy justified? Benchmarking post-market vaccine risks with five commonly used medicinal products in Canada
title Is vaccine hesitancy justified? Benchmarking post-market vaccine risks with five commonly used medicinal products in Canada
title_full Is vaccine hesitancy justified? Benchmarking post-market vaccine risks with five commonly used medicinal products in Canada
title_fullStr Is vaccine hesitancy justified? Benchmarking post-market vaccine risks with five commonly used medicinal products in Canada
title_full_unstemmed Is vaccine hesitancy justified? Benchmarking post-market vaccine risks with five commonly used medicinal products in Canada
title_short Is vaccine hesitancy justified? Benchmarking post-market vaccine risks with five commonly used medicinal products in Canada
title_sort is vaccine hesitancy justified? benchmarking post-market vaccine risks with five commonly used medicinal products in canada
topic Special Section on COVID-19: Quantitative Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853333/
https://www.ncbi.nlm.nih.gov/pubmed/35149970
http://dx.doi.org/10.17269/s41997-022-00609-9
work_keys_str_mv AT maitytuhin isvaccinehesitancyjustifiedbenchmarkingpostmarketvaccineriskswithfivecommonlyusedmedicinalproductsincanada
AT vonschlegellahmad isvaccinehesitancyjustifiedbenchmarkingpostmarketvaccineriskswithfivecommonlyusedmedicinalproductsincanada
AT longochristopher isvaccinehesitancyjustifiedbenchmarkingpostmarketvaccineriskswithfivecommonlyusedmedicinalproductsincanada